Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hi-Tech Pharmacal settles patent litigation with MedPointe
Hi-Tech said that under the terms of the settlement and release agreement, the company will immediately cease distribution of its generic version of Tussi-12 DS and will also
Hi-Tech said that under the terms of the settlement and release agreement, the company will immediately cease distribution of its generic version of Tussi-12 DS and will also
The final data from the randomized phase II clinical trial in 80 patients with metastatic colorectal cancer treated with HyCAMP versus Pfizer’s Camptosar, showed that HyCAMP exerted superior
The nucleic acid testing technology is used for detecting the presence of a key tissue marker in prostate cancer, methylated GST-Pi. LabCorp is the first full-service, national clinical
California-based Impax said that it plans to launch the product soon. US sales of the combined branded and generic 0.5mg, 1mg, 2mg and 3mg dosage forms were approximately
The phase IIb placebo controlled trial to assess the drug, DP-b99, was completed in December 2006. The study enrolled 150 ischemic stroke patients with signs of cortical involvement
These products have been present in the market for over 10 years and have been utilized in the treatment of acne, dermatitis, psoriasis, fungal infections and scabies. The
MedImmune submitted the supplemental biologics license application to extend the age application of FluMist to include children under five years of age that do not have a history
Clofarabine is branded as Clolar in the US and Canada, where it is marketed by Genzyme for relapsed and refractory pediatric acute lymphoblastic leukemia patients (ALL). Bioenvision markets
The FDA’s Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will jointly review Tysabri, a humanized monoclonal antibody, for the treatment of Crohn’s disease
The purpose of the single center, open-label study will be to determine progression free survival (PFS), pharmacokinetics and safety in glioblastoma multiforme (GBM) patients receiving orally- administered Panzem